What Apyx Medical does

Apyx Medical Corporation is a publicly traded medical device company (NASDAQ: APYX) headquartered in Clearwater, Florida, that designs and manufactures energy-based surgical systems for the cosmetic and hospital surgical markets. The company's proprietary Helium Plasma Platform Technology combines helium plasma with radiofrequency (RF) energy to deliver controlled tissue heating to approximately 85°C, enabling soft tissue contraction, collagen production, and tissue remodeling. This platform underpins three product lines: Renuvion (cosmetic and aesthetic surgery), J-Plasma (hospital-based electrosurgical cutting, coagulation, and ablation), and the AYON Body Contouring System (the first FDA-cleared all-in-one body contouring platform, commercially launched in the U.S. in September 2025 after May 2025 FDA clearance). Renuvion is the only FDA-cleared device indicated for use after liposuction, improving loose skin on the neck and chin, and contracting subcutaneous soft tissue anywhere on the body.

The company's commercial model combines capital equipment sales (Renuvion, AYON, and Apyx One generators) with a recurring single-use handpiece revenue stream per procedure. Apyx sells primarily through a direct enterprise field sales force targeting board-certified plastic surgeons, cosmetic surgeons, and hospital surgical departments, supplemented by KOL events, clinical symposia, consumer-facing initiatives (such as the Miami Swim Week showcase), and a 'Find a Provider' patient referral system. Revenue is generated across three streams: Surgical Aesthetics (Renuvion and AYON products), Hospital Surgical (J-Plasma), and OEM agreements (including a 10-year generator manufacturing and supply agreement with Symmetry Surgical). The company has been expanding internationally with commercial launches in South Korea (Q4 2025) and China (July 2025), and has received multiple FDA 510(k) clearances including the May 2026 expanded indication adding power liposuction to AYON.

For the 2025 fiscal year, Apyx reported preliminary revenue of approximately $52.8M, with Q4 2025 revenue of $19.2M representing 34% year-over-year growth. Q1 2026 revenue of $12.5M grew 33% year-over-year, with the Surgical Aesthetics segment up 36% and gross margin expanding to 63.5%. The company holds a $31.1M cash position providing runway through 2027, supported by debt facilities with Perceptive Advisors ($45M, 2023) and MidCap Financial ($35M, 2023), as well as a $10M public equity offering completed in November 2025. FY2026 revenue guidance has been raised to $59-60M.

Name

Apyx Medical

Legal name

Apyx Medical Corporation

Website

https://apyxmedical.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

101–250 employees

Short description

Apyx Medical Corporation (NASDAQ: APYX) designs and manufactures energy-based surgical systems, including the Renuvion helium plasma platform, J-Plasma, and the AYON all-in-one body contouring system, serving board-certified plastic surgeons, cosmetic surgeons, and hospital surgical departments.

Ownership category

akta.pro rank

Product category

Surgical Energy Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser) (HLAHADAC)

Keywords

• Surgical energy devices
• Body contouring systems
• Helium plasma technology
• Electrosurgical generators
• Soft tissue contraction

Headquarters

HQ city

Clearwater

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Others

Revenue model

1. Surgical Aesthetics Products: Revenue from sale of Renuvion and AYON generators and single-use handpieces to surgeons and surgical centers. Single-use handpieces represent recurring consumable revenue as procedures are performed. Includes domestic U.S. and international sales.
2. OEM Agreements: Leverages deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. Symmetry Surgical agreement mentioned for generator manufacturing and supply.
3. J-Plasma Hospital Surgical Products: Revenue from J-Plasma products for hospital surgical market, offering surgeons controlled heat delivery for electrosurgical cutting, coagulation and ablation of soft tissue during open surgical procedures.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Apyx Medical Corporation designs, manufactures, and sells energy-based medical devices built on its proprietary Helium Plasma Platform Technology. Its core products are the Renuvion helium plasma + radiofrequency generators and single-use handpieces, the AYON Body Contouring System, and J-Plasma generators, sold to board-certified plastic surgeons, cosmetic surgeons, and hospital surgical departments for soft tissue contraction, body contouring, and electrosurgical cutting/coagulation/ablation procedures.

Product overview

Apyx Medical offers a portfolio of energy-based medical devices centered on its proprietary Helium Plasma Platform Technology. The core product family includes Renuvion (for cosmetic surgery), J-Plasma (for hospital surgical procedures), and the AYON Body Contouring System (an all-in-one platform). Renuvion provides helium plasma and RF tissue contraction using a unique combination of helium gas and radiofrequency energy. The AYON System integrates Renuvion technology with multiple body contouring modalities including ultrasound-assisted liposuction, power-assisted liposuction, electrosurgery, dual aspiration, and infiltration into a unified platform. The company also leverages its technology through OEM agreements with other medical device manufacturers and sells the Apyx One Console system. Renuvion is the only FDA-cleared device for post-liposuction tissue contraction, neck/chin skin tightening, and subcutaneous soft tissue contraction.

Differentiator

Problem solved

Functional benefit

Brands

• Renuvion: Helium Plasma Platform Technology for soft tissue contraction in cosmetic surgery; FDA-cleared device for use after liposuction and for improving loose skin on neck and chin; #1 trusted body contouring technology among plastic surgeons
• AYON
• J-Plasma
• Apyx One

Products and services

• Renuvion Helium plasma and radiofrequency generator and single-use handpieces for plastic and cosmetic surgeons that heat subdermal tissue to approximately 85°C to contract soft tissue, tighten skin, and stimulate collagen. The only FDA-cleared device for use after liposuction, for improving loose skin on the neck and chin, and for contracting subcutaneous soft tissue anywhere on the body. Supported by 90+ clinical papers.
• AYON Body Contouring System First FDA-cleared all-in-one body contouring system that integrates advanced ultrasound-assisted liposuction, power liposuction, Renuvion tissue contraction, electrosurgical capabilities, dual aspiration, infiltration, and closed-loop contouring into a single platform. Features Smart LIFT technology for real-time energy adjustments. Designed for the aesthetic surgical suite.
• J-Plasma Helium plasma-based generator and handpieces for hospital surgical departments that deliver controlled heat to soft tissue for electrosurgical cutting, coagulation, and ablation during open surgical procedures.
• Apyx One Console Generator console and single-use handpieces for cosmetic surgical procedures, including the APYX-JS3, APYX-RS3, and APYX-ONE generator units. Approved for commercial launch in South Korea targeting the cosmetic surgery market.
• OEM Manufacturing and Waveform Licensing OEM agreements under which Apyx Medical licenses its proprietary waveform technology and manufactures generators for other medical device companies, leveraging decades of expertise in unique energy waveforms (e.g., Symmetry Surgical generator manufacturing and supply agreement).

Quantifiable outcome

• 81.8% of patients showed improvement in cellulitis appearance at 180 days when Renuvion paired with Avéli
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered minor.

• Tiger Aesthetics Medical (Avéli)minorStrategic or Co-development Partner · 21 May 2026Clinical collaboration evaluating combination treatment using Avéli for targeted subcision to disrupt fibrous septae, followed by Renuvion for skin laxity reduction through controlled helium plasma radiofrequency energy. Study published in Aesthetic Surgery Journal Open Forum showing 81.8% patient improvement at 180 days.
• Symmetry SurgicalminorOEM/ Whitelabel/ Licensing Partner10-year generator manufacturing and supply agreement under Apyx Medical's OEM business segment. Symmetry Surgical manufactures and supplies generators using Apyx's unique waveform technology.

Scale indicators11 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• InMode: InMode develops and markets energy-based aesthetic devices for body contouring, skin tightening, and facial aesthetics. It directly competes with Apyx's Renuvion in minimally invasive tissue contraction and shares the same surgeon customer base.
• BTL Industries: BTL markets EMSCULPT, EMSELLA, and other non-invasive body contouring and aesthetic platforms. It competes with Renuvion and AYON for the same plastic surgeon and medspa accounts pursuing body shaping and skin tightening procedures.
• Cutera: Cutera manufactures laser and energy-based aesthetic systems for skin rejuvenation, body contouring, and vascular lesions. It overlaps with Apyx's surgeon-facing aesthetic channel and competes for capital equipment budgets in dermatology and plastic surgery practices.
• Cynosure (Hologic Aesthetics): Cynosure offers a broad portfolio of aesthetic energy devices (lasers, RF, body contouring). It competes with both Renuvion and AYON in plastic surgery and aesthetic medicine channels.
• Solta Medical (Bausch Health): Solta markets Thermage (RF-based skin tightening) and other aesthetic systems. Its Thermage franchise is the closest direct substitute to Renuvion's skin tightening indication.

Emerging players

• Venus Concept: Venus Concept markets energy-based aesthetic devices (Venus Bliss, Venus Legacy) targeting body contouring and skin tightening. It overlaps with Apyx's surgical aesthetics segment with a focus on minimally invasive procedures.
• Sciton: Sciton produces aesthetic and medical laser/light platforms used by plastic surgeons and dermatologists. Its portfolio overlaps with Renuvion's physician channel, particularly in skin rejuvenation and tightening.

Broad incumbents

• Conmed: Conmed manufactures electrosurgical generators and instruments for hospital surgical markets, directly comparable to Apyx's J-Plasma legacy hospital business. It is a much larger diversified medtech player serving similar surgical energy buyers.
• Olympus: Olympus has a substantial surgical energy portfolio (acquired from Gyrus ACMI) overlapping with J-Plasma in hospital electrosurgery. Apyx CEO Charles Goodwin previously held commercial leadership roles at Olympus/Gyrus.
• Stryker: Stryker's surgical equipment segment includes electrosurgical and energy-based devices for hospital ORs, comparable to J-Plasma's hospital surgical market. It is a much larger diversified incumbent in the same buyer accounts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/BovieMed
• Facebookfacebook.com/boviemedical
• Instagraminstagram.com/renuvion
• Pinterestpinterest.com/ApyxMedical

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds8 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apyx Medical